Anthem Biosciences Ltd IPO
Open Demat Account
Anthem Biosciences Ltd IPO Details
Details
| Total Shares Offered | Offer to Public | Retail Max (Shares) | Pre Issue Promoters Holding | Exchange | Issue size |
|---|---|---|---|---|---|
| ₹ 595.61 L | ₹ 595.61 L | ₹ 207.96 L | ₹ 4,317.48 L | BSE | ₹ 3395 Cr |
| IPO Open Date | Close Date | Lot Size | Min Investment | Issue Type | Listing Date |
| 14 Jul, 25 | 16 Jul, 25 | 26 | ₹ 14,040 | Book Building | 21 Jul, 25 |
Anthem Biosciences Ltd IPO Dates
Details
| Sector | Type |
|---|---|
| Sector | Pharmaceuticals - Indian - Bulk Drugs & Formln |
| Sub Sector | NA |
| Issue Type | Book Building |
Subscription Status
*Values are in Lakhs
| Investor Type | Subscription Times | Shares Offered* | Shares Bid* |
|---|---|---|---|
| QIB | 0x | 29708334 | 0 |
| NII | 0x | 8912500 | 0 |
| Retail | 0x | 20795833 | 0 |
| Employee | 0x | 144737 | 0 |
| Total | 0x | 59561404 | 0 |
Subscription Status
Investor Type
QIB
NII
Retail
Employee
Total
*Values are in Lakhs
Anthem Biosciences Ltd Financial Status
Income Statement
Balance Sheet
| Particulars (in Rs. Crores) | FY23 | FY22 | FY21 |
|---|---|---|---|
| Revenue from operations | 561.48 | 604.35 | 427.98 |
| EBITDA | 625.18 | 662.11 | 490.38 |
| PAT | 385.67 | 405.99 | 271.31 |
| Total Assets | 851.66 | 840.04 | 420.40 |
| Share Capital | 114.10 | 8.78 | 8.48 |
| Total Borrowings | 219.31 | 142.24 | 190.08 |
| Operating Activities (Net Cash) | 449.37 | 463.75 | 333.71 |
| Investing Activities (Net Cash) | 355.77 | 120.30 | 190.68 |
| Financing Activities (Net Cash) | 219.31 | 142.24 | 190.08 |
| Net Cashflow | 342.79 | 348.87 | 40.62 |
Particulars (in Rs. Crores)
Revenue from operations
EBITDA
PAT
Total Assets
Share Capital
Total Borrowings
Operating Activities (Net Cash)
Investing Activities (Net Cash)
Financing Activities (Net Cash)
Net Cashflow
About Anthem Biosciences Ltd
Our Company was originally incorporated as Anthem Biosciences Private Limited under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated June 13, 2006, issued by the Registrar of Companies, Karnataka at Bengaluru (RoC). Subsequently, our Company was converted from a private company to a public company, pursuant to a board resolution dated October 18, 2024 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2024 following which the name of our Company was changed to Anthem Biosciences Limited and a certificate of incorporation consequent upon conversion to public limited company was issued by the RoC on December 10, 2024.
According to the F&S Report, the global pharmaceutical industry is projected to grow to U.S.$ 2,076.0 billion by 2029, and CROs and CDMOs are increasingly combining their services to establish integrated CRDMO business models. According to the F&S Report, the Indian CRDMO industry is expected to grow at a CAGR of 13.4% from 2024 to 2029 to reach an estimated value of U.S.$ 15.4 billion, which outpaces the global industry rate of 9.1% and other markets, although pharma companies are subject to challenges such as cost pressures, low rate of experimental compounds moving to commercialization stage and increased regulatory oversight.
We are an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. We provide end to end CRDMO services and we serve a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. Our CRDMO platform comprises 5 main modalities (RNAi, ADC, peptides, lipids and oligonucleotides) and 4 manufacturing capabilities (custom synthesis, flow chemistry, fermentation and biotransformation). We derive revenue primarily from our CRDMO services, including developmental and commercial manufacturing, and research and development services. We also generate revenue from the manufacture and sale of specialty ingredients.
Peer Comparison:
- Anthem Biosciences Ltd.
- Syngene Internatio nal Limited
- Sai Life Sciences Limited
- Cohance Lifescienc es Limited
- Divi's Laboratori es Limited
Anthem Biosciences Ltd IPO Key Points
Strengths
- The Company offers comprehensive one-stop service capabilities across the drug life cycle (drug discovery, development and manufacturing) for both small molecules and biologics and it is the fastest growing Indian CRDMO.
- Its innovation-focused approach has enabled it to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.
- Wide specialty ingredients portfolio, well positioned to capitalize on the large market opportunity for niche specialty ingredients such as GLP-1, fermentation-based products,
- Fully built-out automated manufacturing infrastructure with a consistent regulatory compliance track record.
Risk
- Its business depends on the demand for the company CRDMO services, which contributed to 81.65% of its revenue from operations in Fiscal 2025. Any adverse impact on its CRDMO customers' business or the industries in which they operate may have a material adverse effect on the company business.
- Developmental and commercial manufacturing contributed to 70.78% of its revenue from operations and 71.90% of the company total number of Projects in Fiscal 2025. Its business may be adversely affected by a failures in early phase developmental Projects or a failures to develop or manufacture commercially viable drugs, including for reasons that are not within its control.
- Its financial performance is dependent on the success of the molecules the company manufacture, and its revenue from operations decreased in Fiscal 2023 compared to Fiscal 2022, partly attributable to the failures of a phase III molecule and withdrawal of a commercialized molecule. Accordingly, any unfavorable developments affecting these molecules' success rates, including failures to obtain the required regulatory approvals or withdrawal of commercialized molecules, may have an adverse impact on its business, financial condition, results of operations and prospects.
Strategy
- Continue to expand its technological capabilities to gain wallet share and to win new customers in the discovery and development phase.
- Leverage on its manufacturing capacity to cater to the expected increase in commercialized and late stage molecules.
- Focus on growing its complex specialty ingredients business with large market opportunity.
- Complement its overall growth through identifying opportunities for inorganic expansion.
- The Company offers comprehensive one-stop service capabilities across the drug life cycle (drug discovery, development and manufacturing) for both small molecules and biologics and it is the fastest growing Indian CRDMO.
- Its innovation-focused approach has enabled it to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.
- Wide specialty ingredients portfolio, well positioned to capitalize on the large market opportunity for niche specialty ingredients such as GLP-1, fermentation-based products,
- Fully built-out automated manufacturing infrastructure with a consistent regulatory compliance track record.
How To Apply for Anthem Biosciences Ltd IPO Online?
Step 1:
Log in to the BlinkX stock market app and click ‘IPO’ in the Xplore section.
Step 2:
From the list of open IPOs, select the IPO you want to invest.
Step 3:
Go through the IPO details like lot size, price band, about the company, etc.
Step 4:
Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.
Step 5:
Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.
